Treatment
mFOLFOX6 clinical trials
We’re tracking 27 recruiting studies that include mFOLFOX6, each written for real people, not researchers, below.
Recruiting studies
- NCT06791512RecruitingPhase 3
Chemo Plus Targeted Therapy With or Without Immunotherapy for Colorectal Cancer
This trial compares a standard chemotherapy combination (mFOLFOX6) plus a targeted drug (bevacizumab) with or without an immunotherapy (PD-1 antibody) for locally advanced colorectal cancer. It aims to see if adding the immunotherapy improves outcomes for patients with a specific tumor type (pMMR/MSS).
Guangzhou, GuangdongAges 18–80 - NCT06662786RecruitingPhase 3
Amivantamab plus chemo vs. standard chemo for left-sided colorectal cancer
This trial compares a new combination (amivantamab plus chemotherapy) with the standard treatment (cetuximab plus chemotherapy) as the first therapy for people with left-sided colorectal cancer that has spread. The goal is to see which approach works better when the tumor has no mutations in the KRAS, NRAS, or BRAF genes.
Gilbert, ArizonaAges 18 years+ - NCT07789210RecruitingPhase 2
Neoadjuvant targeted therapy for BRAF-mutant colorectal cancer
This trial is testing a combination of two targeted drugs (encorafenib and cetuximab) with standard chemotherapy before surgery in people with a specific type of colorectal cancer that has the BRAF V600E mutation and is locally advanced or has limited spread. The goal is to see if this treatment can shrink tumors and improve outcomes.
Hangzhou, ZhejiangAges 18–75 - NCT05174169RecruitingPhase 2/Phase 3
Adjuvant colon chemotherapy guided by tumor DNA results
This trial tests whether treatment for colon cancer after surgery can be guided by a blood test that looks for leftover cancer signals (ctDNA). It may help some people choose stronger or different chemo based on whether ctDNA is found after surgery.
Birmingham, AlabamaAges 18 years+ - NCT05571644RecruitingPhase 2
Study compares two pre-surgery treatments for locally advanced rectal cancer
This Phase 2 trial tests whether a newer combination chemotherapy plus an immunotherapy medicine (cadonilimab/AK104) works better than standard chemotherapy before surgery for locally advanced colorectal cancer. The goal is to shrink the tumor and improve how well treatment works after surgery.
Guangzhou, GuangdongAges 18–70 - NCT06002789RecruitingPhase 2
PD-1 immunotherapy with or without chemo before surgery for colorectal cancer
This trial tests a medicine called PD-1 (a type of immunotherapy that helps your immune system fight cancer), sometimes with chemotherapy, before surgery for a certain type of colorectal cancer. It is for people whose tumors have a specific DNA repair problem (dMMR or MSI-H) and whose cancer has not spread to distant organs.
Guangzhou, GuangdongAges 18–80 - NCT07790510RecruitingPhase 1/Phase 2
Study of HSK42360 with cetuximab for BRAF-mutated colorectal cancer
This trial tests an experimental drug (HSK42360-Na) combined with standard treatments (cetuximab with or without chemotherapy) for people with advanced colorectal cancer that has a specific BRAF mutation. The goal is to see if this combination can shrink tumors or slow their growth, and to check its safety.
BeijingAges 18 years+ - NCT07659795RecruitingPhase 2
Study of VS-7375 for KRAS G12D colorectal cancer
This trial tests a new targeted pill, VS-7375, for people with a specific type of advanced colorectal cancer called KRAS G12D. It's for those who either haven't had treatment yet or whose cancer has worsened after prior therapy.
Los Angeles, CaliforniaAges 18 years+ - NCT07702032RecruitingPhase 3
Study of petosemtamab plus chemo for left-sided colorectal cancer
This trial tests a new drug (petosemtamab) plus standard chemo to see if it works better than the current standard (cetuximab plus chemo) for people with advanced left-sided colorectal cancer that has not been treated yet. It is for patients whose cancer cells have no RAS or BRAF mutations.
Olympia, WashingtonAges 18 years+ - NCT06324357RecruitingPhase 1/Phase 2
Zongertinib for HER2-positive cancers that have spread
This trial tests a new pill called zongertinib, alone or with other drugs, for people with HER2-positive cancers (like breast, stomach, or colorectal cancer) that have spread and are no longer responding to standard treatments. The goal is to find the best dose and see if it can help shrink tumors or slow the disease.
Cerritos, CaliforniaAges 18 years+ - NCT06650332RecruitingPhase 1/Phase 2
Cadonilimab combo for first-line HER2-positive gastric cancer
This trial tests a new combination treatment (cadonilimab plus chemotherapy) as the first therapy for people with advanced gastric or gastroesophageal junction cancer that has a certain amount of HER2 protein. It aims to see if this combination can shrink tumors and help people live longer.
Hangzhou, ZhejiangAges 18–75 - NCT06590259RecruitingPhase 2
Ablation plus drug therapy for colorectal cancer liver metastases
This trial tests a combination treatment that uses heat or cold (ablation) to destroy liver tumors along with medicines that boost your immune system to fight cancer. It is for people whose colorectal cancer has spread to the liver and who could not have surgery, or whose first treatment stopped working.
ShanghaiAges 18–75 - NCT04120701RecruitingPhase 3
Using blood DNA tests to guide colon cancer treatment after surgery
This trial tests whether a blood test that looks at cancer DNA can help decide whether you need “adjuvant” (extra) chemotherapy after colon cancer surgery. It may help some patients avoid unnecessary chemotherapy while still keeping the cancer from coming back.
DijonAges 18–75 - NCT05253651RecruitingPhase 3
Tucatinib plus trastuzumab with chemo for HER2+ metastatic colon cancer
This trial tests whether adding tucatinib and trastuzumab to standard chemotherapy works better than standard treatment alone for people with HER2-positive metastatic colon or rectal cancer. It aims to improve how long people live and how well tumors respond as first treatment for advanced disease.
Glendale, ArizonaAges 18 years+ - NCT06948448RecruitingPhase 2
New treatment for advanced colorectal cancer with PD-L1 biomarker
This trial tests a new drug (ONO-4578) combined with standard chemotherapy and immunotherapy for people with advanced colorectal cancer that has not been treated before and has a specific marker called PD-L1. The goal is to see if this combination works better than the usual treatment.
Phoenix, ArizonaAges 18 years+ - NCT04595864RecruitingPhase 3
Chemotherapy into the liver before transplant for liver cancer
This trial tests whether giving chemotherapy directly into the liver blood supply before a liver transplant can help people with liver cancer that is beyond standard transplant criteria. It may help lower cancer risk around the time of transplant while keeping people healthy enough to receive the transplant.
Nanjing, JiangsuAges 18–75 - NCT05008809RecruitingPhase 3
FIRE-9 trial: chemo after colon cancer metastasis removal
This trial studies whether giving chemotherapy after surgery or ablation (destroying spots of cancer) can improve outcomes in people with metastatic colon or rectal cancer. It compares post-treatment chemotherapy strategies to reduce the chance the cancer comes back.
AmbergAges 18 years+ - NCT05959356RecruitingPhase 2
First-line treatment for left-sided metastatic colon cancer with specific tumor markers
This Phase 2 trial tests a combination of medicines (cetuximab, envafolimab, and chemotherapy) as the first treatment for certain left-sided metastatic colorectal cancers. It may help by slowing or shrinking the cancer in people whose tumor has no RAS/BRAF mutations and is microsatellite-stable (MSS).
Foshan, GuangdongAges 18 years+ - NCT06162650RecruitingPhase 2
Pre-surgery chemo-radiation therapy for rectal cancer
This trial tests a combination of chemotherapy and radiation therapy before surgery for people with mid or low rectal cancer that hasn't spread. The goal is to see if this approach works better than current treatments.
TainanAges 20 years+ - NCT06445062RecruitingPhase 1/Phase 2
Study of new RAS inhibitors for GI solid tumors
This trial tests new drugs that target specific RAS mutations in advanced gastrointestinal cancers, like pancreatic or colorectal cancer. It aims to see if these drugs can shrink tumors or slow their growth.
Chandler, ArizonaAges 18 years+ - NCT06621563RecruitingPhase 1
Study of HS-20117 Combination Therapy for Advanced Solid Tumors
This early-phase trial tests a new drug (HS-20117) combined with other drugs for people with advanced solid tumors. It aims to see if the combination is safe and effective, especially for cancers that have not responded to other treatments.
TianjinAges 18–75 - NCT06812728RecruitingPhase 2
Chemo and radiation before surgery for advanced rectal cancer
This trial tests giving a strong chemotherapy combination (FOLFIRINOX) followed by radiation before surgery for locally advanced rectal cancer. If you have stage 3 or high-risk stage 2 rectal cancer that has not spread, this approach may shrink the tumor and improve outcomes.
Shibīn al Kawm, MenoufiaAges 18–70 - NCT06835569RecruitingPhase 1
ALTA3263 for advanced KRAS-mutated solid tumors
This trial tests an experimental pill called ALTA3263 for adults with advanced solid tumors that have a specific KRAS mutation. It's for people who have already tried other treatments or can't take them.
Orlando, FloridaAges 18 years+ - NCT06917079RecruitingPhase 1
BBO-11818 for KRAS-mutated cancers
This trial tests a new oral drug (BBO-11818) for people with solid tumors that have a specific KRAS mutation. It's for those whose cancer has spread or cannot be removed by surgery and who have not had other cancers recently.
Los Angeles, CaliforniaAges 18 years+
What mFOLFOX6 is being studied for
Conditions with recruiting mFOLFOX6 studies.
Common questions
- Are there clinical trials studying mFOLFOX6?
- Yes. Clin2 currently lists 27 recruiting studies that include mFOLFOX6, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a mFOLFOX6 trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is mFOLFOX6 an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether mFOLFOX6 or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.